These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 27159764)

  • 1. Utilization and Toxicity of Alternative Delivery Methods of Adjuvant Chemotherapy for Ovarian Cancer.
    Wright JD; Hou JY; Burke WM; Tergas AI; Chen L; Hu JC; Ananth CV; Neugut AI; Hershman DL
    Obstet Gynecol; 2016 Jun; 127(6):985-991. PubMed ID: 27159764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization and Outcomes of Chemotherapy in Women With Intermediate-Risk, Early-Stage Ovarian Cancer.
    Chatterjee S; Chen L; Tergas AI; Burke WM; Hou JY; Hu JC; Ananth CV; Neugut AI; Hershman DL; Wright JD
    Obstet Gynecol; 2016 Jun; 127(6):992-1002. PubMed ID: 27159756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
    Armstrong DK; Bundy B; Wenzel L; Huang HQ; Baergen R; Lele S; Copeland LJ; Walker JL; Burger RA;
    N Engl J Med; 2006 Jan; 354(1):34-43. PubMed ID: 16394300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
    Becker DA; Thomas ED; Gilbert AL; Boone JD; Straughn JM; Huh WK; Bevis KS; Leath CA; Alvarez RD
    Gynecol Oncol; 2016 Jul; 142(1):25-29. PubMed ID: 27130405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicities, complications, and clinical encounters during intraperitoneal chemotherapy in 17 women with ovarian cancer.
    Sun V; Otis-Green S; Morgan R; Wakabayashi M; Hakim A; Callado ME; Yang E; Ferrell B; Grant M
    Eur J Oncol Nurs; 2013 Jun; 17(3):375-80. PubMed ID: 23153453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
    Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
    Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
    Schlappe BA; Mueller JJ; Zivanovic O; Gardner GJ; Long Roche K; Sonoda Y; Chi DS; O'Cearbhaill RE
    Gynecol Oncol; 2016 Jul; 142(1):13-18. PubMed ID: 27189456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
    Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparisons of Clinical Outcomes in Women with Advanced Ovarian Cancer Treated with Frontline Intraperitoneal versus Dose-Dense Platinum/Paclitaxel Chemotherapy without Bevacizumab.
    Ting WH; Hsiao CH; Chen HH; Wei MC; Lin HH; Hsiao SM
    Int J Environ Res Public Health; 2020 May; 17(10):. PubMed ID: 32443934
    [No Abstract]   [Full Text] [Related]  

  • 10. Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer.
    Nicoletto MO; Dalla Palma M; Donach ME; Gusella M; Cappetta A; Shams M; Marchet A; Nardin M; Pintacuda G; Di Maggio A; Marchesi M; Carli P; Fiduccia P; Artioli G; Nitti D
    Tumori; 2010; 96(6):918-25. PubMed ID: 21388052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of care and outcomes for women with uterine cancer and ovarian metastases.
    Jones NL; Huang Y; Chatterjee S; Tergas AI; Burke WM; Hou JY; Deutsch I; Ananth CV; Neugut AI; Hershman DL; Wright JD
    Int J Gynecol Cancer; 2019 Feb; 29(2):365-376. PubMed ID: 30718315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of grade 3/4 toxicity associated with intraperitoneal chemotherapy administered after primary versus interval surgical debulking in ovarian cancer.
    Le T; Latifah H; Jolicoeur L; Faught W; Weberpals J; Hopkins L; Fung-Kee-Fung M
    Int J Gynecol Cancer; 2011 Jul; 21(5):811-5. PubMed ID: 21412160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
    Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and safety of a modified outpatient regimen with intravenous/intraperitoneal chemotherapy for optimally debulked stage III ovarian cancer.
    Bruixola G; Domingo S; Díaz R; Caballero J; Palomar L; De La Cueva H; Santaballa A
    Int J Gynecol Cancer; 2015 Feb; 25(2):214-21. PubMed ID: 25415075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?
    Monk BJ; Chan JK
    Ann Oncol; 2017 Nov; 28(suppl_8):viii40-viii45. PubMed ID: 29232474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.
    Bixel K; Vetter M; Davidson B; Berchuck A; Cohn D; Copeland L; Fowler JM; Havrilesky L; Lee PS; O'Malley DM; Salani R; Valea F; Alvarez Secord A; Backes F
    Gynecol Oncol; 2020 Mar; 156(3):530-534. PubMed ID: 31937450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative study of different chemotherapy approaches for advanced epithelial ovarian cancer].
    Chen YL; Liu YQ; Tang DH; Chu CN
    Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):110-4. PubMed ID: 18683749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer.
    Tanner EJ; Black DR; Zivanovic O; Kehoe SM; Dao F; Konner JA; Barakat RR; Lichtman SM; Levine DA
    Gynecol Oncol; 2012 Jan; 124(1):59-62. PubMed ID: 21982046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal chemotherapy for women with ovarian cancer: nursing care and considerations.
    Potter KL; Held-Warmkessel J
    Clin J Oncol Nurs; 2008 Apr; 12(2):265-71. PubMed ID: 18390462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.